Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit.

Psychopharmacology
Alessandro GozziAngelo Bifone

Abstract

Several second-generation antipsychotics are characterised by a significant antagonistic effect at serotonin 5-HT(2A) receptors (5-HT(2A)R), a feature that has been associated with lower incidence of extra-pyramidal symptoms and a putative amelioration of positive and negative symptoms experienced by schizophrenic patients. However, the neurofunctional substrate of 5-HT(2A) antagonism and its exact contribution to the complex pharmacological profile of these drugs remain to be elucidated. Here, we used pharmacological magnetic resonance imaging to map the modulatory effects of the selective 5-HT(2A)R antagonist Ml00907 on the spatiotemporal patterns of brain activity elicited by acute phencyclidine (PCP) challenge in the rat. PCP is a non-competitive NMDA receptor antagonist that induces dysregulation of corticolimbic glutamatergic neurotransmission and produces cognitive impairment and psychotic-like symptoms reminiscent of those observed in schizophrenia. Pre-administration of M100907 produced focal and region-dependent attenuation of PCP-induced response in frontoseptohippocampal areas. As early studies highlighted a permissive role of 5-HT(2A)R on frontal dopamine release, the role of post-synaptic dopamine D(1) receptors o...Continue Reading

References

Sep 1, 1978·The American Journal of Psychiatry·R M Allen, S J Young
Aug 14, 1992·European Journal of Pharmacology·P H AndersenE B Nielsen
Nov 1, 1992·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K J WorsleyP Neelin
Jan 1, 1992·Journal of Neural Transmission. General Section·M L Wadenberg
Dec 1, 1987·Brain Research·A D WeissmanE D London
Oct 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·N D VolkowR Cancro
Dec 1, 1986·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·J HennigH Friedburg
Nov 9, 1995·Nature·D A SilbersweigL Schnorr
Dec 15, 1994·The Journal of Physiology·P Piguet, M Galvan
Jan 19, 1995·Nature
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A K MalhotraA Breier
Apr 16, 1998·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·J B MandevilleR M Weisskoff
Mar 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G B VartyM A Geyer
May 14, 1999·Current Opinion in Neurobiology·R J DavidsonK Putnam
May 27, 1999·Molecular and Chemical Neuropathology·K A Skau, C G Triplett
Jun 24, 1999·The Journal of Comparative Neurology·V Cornea-HébertL Descarries
Aug 27, 1999·Psychopharmacology·J H KrystalD S Charney
Mar 17, 2000·Brain Research. Brain Research Reviews·G K Aghajanian, G J Marek
Nov 4, 2000·The British Journal of Psychiatry : the Journal of Mental Science·P F LiddleE T Ngan
Dec 6, 2001·Hippocampus·D R MedoffC A Tamminga
Jul 2, 2002·Archives of General Psychiatry·John H KrystalBita Moghaddam
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yan ZhaiLaura K Nisenbaum

❮ Previous
Next ❯

Citations

Jul 22, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alessandro GozziAngelo Bifone
Nov 4, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alessandro GozziMarina Bentivoglio
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Oct 8, 2013·Biological Psychiatry·Jason R Tregellas
Jan 24, 2016·NeuroImage·Marco PaganiAlessandro Gozzi
Sep 14, 2012·Expert Opinion on Drug Discovery·Angelo Bifone, Alessandro Gozzi
Mar 7, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Masae AraiAtsuhiro Sakamoto
Nov 10, 2011·Journal of Neuroscience Methods·Livia FerrariAlessandro Gozzi
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
Jun 20, 2015·International Journal of Endocrinology·Duo ZhangHeng Meng
Feb 4, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Edith J LiemburgAndré Aleman
Jun 6, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alessandro GozziAngelo Bifone
Feb 2, 2013·The Journal of Pharmacology and Experimental Therapeutics·Lino BecerraDavid Borsook
Sep 26, 2013·International Journal of Molecular Medicine·Yoko HoriAtsuhiro Sakamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here